



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 20, 2003

Signature:

Mary Jane DiPalma
(Mary Jane DiPalma)

Docket No.: CWRU 2002-0

TECHNICAL CENTER 1600/2900

MAR 31 2003

RECEIVED

#9
JRL
6/6/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gerson et al.

Application No.: 10/079049

Group Art Unit: 1614

Filed: February 19, 2002

Examiner: Krass, F.F.

For: METHOXYAMINE COMBINATIONS IN
THE TREATMENT OF CANCER

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Rejection or Notice of Allowance, whichever occurred first, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

A copy of each reference on PTO/SB/08 is attached.

Those patent(s) or publication(s) which are not marked with an asterisk (*) in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in prior application no. 09/373,693 filed August 13, 1999 which is relied upon in this application for an earlier filing date under 35 U.S.C. 120.

03/27/2003 BNGUYEN1 00000112 181945 10079049

02 FC:1806 180.00 CH

Adjustment date: 06/12/2003 EEKUBAY1

03/27/2003 BNGUYEN1 00000112 181945 10079049


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CWRU-P02-015.

Dated: 3/20/03

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant